اخبار و اعلانات

 آمار

تعداد نشریات286
تعداد نشریات سازمان84
تعداد شماره‌ها2,848
تعداد مقالات32,322
تعداد مشاهده مقاله41,448,014
تعداد دریافت فایل اصل مقاله18,648,806
AL-Hadrawy, S. M. J, Mahdi AL-Turfi, Z. S. (1400). Effects of the Long-term Treatment of Proton Pump Inhibitors on the Function of Kidney and Liver in Laboratory Female Rats. سامانه مدیریت نشریات علمی, 76(4), 975-983. doi: 10.22092/ari.2021.355947.1745
S. M. J AL-Hadrawy; Z. S Mahdi AL-Turfi. "Effects of the Long-term Treatment of Proton Pump Inhibitors on the Function of Kidney and Liver in Laboratory Female Rats". سامانه مدیریت نشریات علمی, 76, 4, 1400, 975-983. doi: 10.22092/ari.2021.355947.1745
AL-Hadrawy, S. M. J, Mahdi AL-Turfi, Z. S. (1400). 'Effects of the Long-term Treatment of Proton Pump Inhibitors on the Function of Kidney and Liver in Laboratory Female Rats', سامانه مدیریت نشریات علمی, 76(4), pp. 975-983. doi: 10.22092/ari.2021.355947.1745
AL-Hadrawy, S. M. J, Mahdi AL-Turfi, Z. S. Effects of the Long-term Treatment of Proton Pump Inhibitors on the Function of Kidney and Liver in Laboratory Female Rats. سامانه مدیریت نشریات علمی, 1400; 76(4): 975-983. doi: 10.22092/ari.2021.355947.1745

Effects of the Long-term Treatment of Proton Pump Inhibitors on the Function of Kidney and Liver in Laboratory Female Rats

Archives of Razi Institute
مقاله 27، دوره 76، شماره 4، آذر و دی 2021، صفحه 975-983    اصل مقاله (820.67 K)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.22092/ari.2021.355947.1745
نویسندگان
S. M. J AL-Hadrawy* 1؛ Z. S Mahdi AL-Turfi2
1Department of Biology, Faculty of Sciences, University of Kufa, Iraq
2Department of Biology, Faculty of Education for Girls, University of Kufa, Iraq
چکیده
Proton pump inhibitors (PPIs) are a group of medications effectively used to inhibit gastric acid secretion and to treat many acid-related disorders, including gastroesophageal reflux disease and other gastric disorders. Recent studies recommended that they may be associated with the risk of chronic kidney disease and liver disease. Therefore, the current study aimed to investigate the effect of long-term treatment with PPIs on kidney and liver function in laboratory rats. Fifteen female albino white rats (Rattusnorvigicus) were randomly assigned to three groups of five animals. The control group was fed regular pellet, group PPI-2 received standard pellet diet and was given esomeprazole (10 mg/kg b.w.) via daily oral gavage in mornings for two weeks, and group PPI-3 was fed standard pellet diet and was given esomeprazole (10 mg/kg b.w.) via daily oral gavage in mornings for three months. Blood samples were taken after 2 weeks and 3 months by cardiac puncture for measuring serum creatinine, urea, total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP).  In addition, kidney and liver tissues were histopathologically evaluated.  Serum creatinine, urea, ALT, total bilirubin, and ALP significantly increased in group PPI-3, compared to other groups. Histopathological study of the kidneys and liver revealed normal histology structure in the control group and the rats of the PPI-2 group, while some histological changes were observed in the liver and kidney of the animals in the PPI-3 group. The histological changes included the widening of Bowman's space and shrunken glomeruli, whereas the renal tubules had congested tubular cells. Furthermore, congestion in the blood vessels and hepatic cells degradation were observed in the liver. These data indicate that the long-term administration of PPIs has adverse effects on the structure and function of the kidney and liver.
کلیدواژه‌ها
Proton pump inhibitor؛ Liver function؛ Kidney function؛ Long-term Treatment؛ Esomeprazole
سایر فایل های مرتبط با مقاله
مراجع
  1. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. Br Med J; 2008; 336(7634):2-3.
  2. Wilhelm SM, Rjater RG, Kale-Pradhan PB. Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Rev Clin Pharmacol. 2013;6(4):443–51.
  3. De Bruyne P, Christiaens T, Vander Stichele R, Van Winckel M. Changes in prescription patterns of acid-suppressant medications by Belgian pediatricians: analysis of the national database,[1997–2009]. J Pediatr Gastroenterol Nutr. 2014;58(2):220–5.
  4. Ahrens D, Chenot J-F, Behrens G, Grimmsmann T, Kochen MM. Appropriateness of treatment recommendations for PPI in hospital discharge letters. Eur J Clin Pharmacol. 2010;66(12):1265–71.
  5. Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: a nested case–control study. BMC Nephrol. 2013;14(1):1–7.
  6. Blank M-L, Parkin L, Paul C, Herbison P. A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int. 2014;86(4):837–44.
  7. Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015;10(6):e0128004.
  8. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies. Cmaj. 2004;171(1):33–8.
  9. Yang Y-X, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. Jama. 2006;296(24):2947–53.
  10. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012;81(5):442–8.
  11. Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016; 176 (2): 238–46. 2015.
  12. Tin A, Grams ME, Maruthur NM, Astor BC, Couper D, Mosley TH, et al. Results from the Atherosclerosis Risk in Communities study suggest that low serum magnesium is associated with incident kidney disease. Kidney Int. 2015;87(4):820–7.
  13. Mohajeri MH, Brummer RJM, Rastall RA, Weersma RK, Harmsen HJM, Faas M, et al. The role of the microbiome for human health: from basic science to clinical applications. Eur J Nutr. 2018;57(1):1–14.
  14. Brandl K, Schnabl B. Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease? Expert Rev Gastroenterol Hepatol. 2015;9(8):1069–76.
  15. Weersink RA, Bouma M, Burger DM, Drenth JPH, Harkes‐Idzinga SF, Hunfeld NGM, et al. Safe use of proton pump inhibitors in patients with cirrhosis. Br J Clin Pharmacol. 2018;84(8):1806–20.
  16. Dultz G, Piiper A, Zeuzem S, Kronenberger B, Waidmann O. Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis. Aliment Pharmacol Ther. 2015;41(5):459–66.
  17. Muriithi AK, Leung N, Valeri AM, Cornell LD, Sethi S, Fidler ME, et al. Biopsy-proven acute interstitial nephritis, 1993-2011: a case series. Am J Kidney Dis. 2014;64(4):558–66.
  18. Berney‐Meyer L, Hung N, Slatter T, Schollum JBW, Kitching AR, Walker RJ. Omeprazole‐induced acute interstitial nephritis: A possible Th 1–Th 17‐mediated injury? Nephrology. 2014;19(6):359–65.
  19. Yepuri G, Sukhovershin R, Nazari-Shafti TZ, Petrascheck M, Ghebre YT, Cooke JP. Proton pump inhibitors accelerate endothelial senescence. Circ Res. 2016;118(12):e36–42.
  20. Ghebremariam YT, LePendu P, Lee JC, Erlanson DA, Slaviero A, Shah NH, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013;128(8):845–53.
  21. Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238–46.
  22. Nochaiwong S, Ruengorn C, Awiphan R, Koyratkoson K, Chaisai C, Noppakun K, et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: A systematic review and meta-Analysis. Nephrol Dial Transplant. 2018;33(2):331–42.
  23. Geevasinga N, Coleman PL, Webster AC, Roger SD. Proton pump inhibitors and acute interstitial nephritis. Clin Gastroenterol Hepatol. 2006;4(5):597–604.
  24. Salib YS, Kandeel S, El-Mehey KA, Zamzam AEEF. Histological study of the effect of proton pump inhibitor (esomeprazole) on the renal cortex of adult male albino rats. Egypt J Histol. 2019;42(3):624–34.
  25. Kinoshita Y, Ishimura N, Ishihara S. Advantages and disadvantages of long-term proton pump inhibitor use. J Neurogastroenterol Motil. 2018;24(2):182–96.
  26. Kim JH, Lim KS, Min YW, Lee H, Min B, Rhee P, et al. Proton pump inhibitors do not increase the risk for recurrent spontaneous bacterial peritonitis in patients with cirrhosis. J Gastroenterol Hepatol. 2017;32(5):1064–70.
  27. Tsai C-F, Chen M-H, Wang Y-P, Chu C-J, Huang Y-H, Lin H-C, et al. Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in a population study. Gastroenterology. 2017;152(1):134–41.
  28. Freedberg DE, Kim LS, Yang Y-X. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152(4):706–15.
  29. Scarpignato C, Gatta L, Zullo A, Blandizzi C. Effective and safe proton pump inhibitor therapy in acid-related diseases–A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):1–35.
  1. Lodato F, Azzaroli F, Di Girolamo M, Feletti V, Cecinato P, Lisotti A, et al. Proton pump inhibitors in cirrhosis: tradition or evidence based practice? World J Gastroenterol WJG. 2008;14(19):2980.
  2. Chen P, Stärkel P, Turner JR, Ho SB, Schnabl B. Dysbiosis‐induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice. Hepatology. 2015;61(3):883–94.
آمار
تعداد مشاهده مقاله: 1,557
تعداد دریافت فایل اصل مقاله: 553


counter
سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب